Compare CARR & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CARR | ARGX |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.6B | 58.4B |
| IPO Year | 2020 | 2017 |
| Metric | CARR | ARGX |
|---|---|---|
| Price | $68.68 | $859.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 19 |
| Target Price | $70.62 | ★ $1,008.56 |
| AVG Volume (30 Days) | ★ 4.8M | 353.9K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $21,747,000,000.00 | N/A |
| Revenue This Year | $2.91 | $44.39 |
| Revenue Next Year | $5.37 | $20.84 |
| P/E Ratio | $247.39 | ★ $33.69 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $50.24 | $560.91 |
| 52 Week High | $81.09 | $953.58 |
| Indicator | CARR | ARGX |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 44.88 |
| Support Level | $65.77 | $832.63 |
| Resistance Level | $76.76 | $939.08 |
| Average True Range (ATR) | 2.10 | 22.42 |
| MACD | -0.42 | -9.02 |
| Stochastic Oscillator | 33.67 | 14.65 |
Carrier Global, spun out of United Technologies in 2020, manufactures and services commercial and residential HVAC systems and transportation refrigeration solutions under its flagship Carrier brand, as well as Bryant, Payne, Heil, and others across various price points. In 2024, Carrier acquired Viessmann Climate Solutions to expand its footprint in Europe with heat pumps, boilers, and solar PV equipment. Proceeds from the sale of Carrier's fire and security (Honeywell) and commercial refrigeration (Haier) businesses reduced debt and focused the company on global HVAC and refrigeration solutions. Carrier generates 75% of sales from equipment and 25% from parts and services. The company derives 50% of revenue from the US, 30% from Europe, and 20% from the Asia-Pacific region.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.